Elucidating the exact pharmacological system of action (MOA) of naturally developing compounds can be tough. Although Tarselli et al. (sixty) formulated the primary de novo artificial pathway to conolidine and showcased this naturally developing compound successfully suppresses responses to equally chemically induced and inflammation-derived pain,